Current Liabilities decreased faster than Third Harmonic Bio Inc 's Cash & cash equivalent, this led to improvement in Third Harmonic Bio Inc 's Quick Ratio to 53.24, Quick Ratio remained below Third Harmonic Bio Inc average.

Within Major Pharmaceutical Preparations industry 5 other companies have achieved higher Quick Ratio than Third Harmonic Bio Inc in first quarter 2025. While Quick Ratio total ranking has improved so far during the Q1 2025 to 42, from total ranking in the fourth quarter 2024 at 46.

Explain Quick Ratio?
How much Cash & cash equivalents THRD�s has?
What are THRD�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

THRD Quick Ratio	(Mar 31 2025) Q1	(Dec 31 2024) Q4	(Sep 30 2024) Q3	(Jun 30 2024) Q2	(Mar 31 2024) Q1
Y / Y Current Liabilities Change	26.98 %	31.21 %	19.99 %	50.41 %	-18.78 %
Y / Y Cash & cash equivalent Change	3.34 %	5.94 %	8.11 %	-8.2 %	-6.87 %
Quick Ratio MRQ	53.24	40.1	41.91	40.2	65.41
THRD's Total Ranking	# 42	# 46	# 48	# 59	# 39
Seq. Current Liabilities Change	-28.23 %	0.62 %	11.22 %	58.09 %	-25.84 %
Seq. Cash & cash equivalent Change	-4.72 %	-3.73 %	15.96 %	-2.85 %	-2.32 %

Quick Ratio first quarter 2025 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 6
Healthcare Sector	# 10
Overall Market	# 42

Quick Ratio Statistics
High	Average	Low
89.76	54.62	40.1
(Sep 30 2022)		(Dec 31 2024)

Financial Statements
Third Harmonic Bio Inc 's Current Liabilities	$ 5 Millions	Visit THRD's Balance sheet
Third Harmonic Bio Inc 's Cash & cash equivalent	$ 272 Millions	Visit THRD's Balance sheet
Source of THRD's Sales		Visit THRD's Sales by Geography

Cumulative Third Harmonic Bio Inc 's Quick Ratio

THRD's Quick Ratio for the trailling 12 Months

THRD Quick Ratio	(Mar 31 2025) 12 Months	(Dec 31 2024) 12 Months	(Sep 30 2024) 12 Months	(Jun 30 2024) 12 Months	(Mar 31 2024) 12 Months
Y / Y Current Liabilities TTM Growth	31.11 %	19.87 %	10.34 %	19.36 %	15.4 %
Y / Y Cash & cash equivalent TTM Growth	2.23 %	-0.36 %	-3.54 %	-7.63 %	8.51 %
Quick Ratio TTM	43.24	44.79	47.4	48.95	55.45
Total Ranking TTM	# 1560	# 1976	# 1823	# 1793	# 1713
Seq. Current Liabilities TTM Growth	4.42 %	7.4 %	5.43 %	10.89 %	-4.54 %
Seq. Cash & cash equivalent TTM Growth	0.8 %	1.48 %	2.09 %	-2.1 %	-1.76 %

Quick ratio ranking by company, industry and sector >> Back to THRD Financial Strength Comparisons >> Go to Compare THRD Quick Ratio to its Competitors

News about Third Harmonic Bio Inc Quick Ratio

Navigating Liquidation Third Harmonic Bios Strategic Exit and Financial Resilience

Abstract Third Harmonic Bio Inc. (THB) has recently undergone significant corporate transformations, including stockholder-approved liquidation and dissolution. Meanwhile, financial ratios reveal a dynamic yet challenging fiscal environment. This article explores the implications of these developments for the company and its stakeholders, providing insight into its performance metrics and market position. In a pivotal turn of events, Third Harmonic Bio Inc. has announced that its stockholders overwhelmingly approved a plan for liquidation and dissolution. This marked a decisive moment for the biopharmaceutical company, which previously advanced the development of THB335 in clinical trials. The focus on liquidation comes as THB335 Phase 1 clinical data showed promise but ultimately could not sustain the company s operational trajectory. Financial Overview Despite facing the necessity of liquidation, recent financial analyses have portrayed a dual narrative for Third Harmonic Bio. Current liabilities have decreased more rapidly than the company s cash and cash equivalents, leading to a notable improvement in its Quick Ratio, which surged to 53.24. Quick Ratio is a crucial measure of a company’s short-term liquidity, evaluating its ability to meet short-term obligations without relying on the sale of inventory. Performance MetricsComparatively, Third Harmonic Bio now stands ahead of the industry average, reflected in its improved Quick Ratio ranking from 40.1 in the fourth quarter of 2024 to 46 in the first quarter of 2025. However, it is essential to recognize that despite these advancements, the company s Quick Ratio remains below the twelve-month average post-liability reductions, with a current trailing figure of 43.24. Furthermore, data indicate that among 314 other companies in the biopharmaceutical sector, Third Harmonic Bio s Quick Ratio ranks lower in terms of superior liquidity metrics.

On the trailing twelve months basis Due to cut in Current Liabilities in the Q1 2025 to $5.10 millions, cumulative Quick Ratio decreased to 43.24 below the average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 315 other companies have achieved higher Quick Ratio than Third Harmonic Bio Inc . While Quick Ratio overall ranking has improved so far to 1560, from total ranking during the twelve months ending fourth quarter 2024 at 1976.

Explain Quick Ratio?
How much Cash & cash equivalents THRD�s has?
What are THRD�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 316
Healthcare Sector	# 586
Within the Market	# 1560

trailing twelve months Quick Ratio Statistics
High	Average	Low
55.45	48.97	38.53
(Mar 31 2024)		(Mar 31 2023)

Companies with similar Quick Ratio in the quarter ending Mar 31 2025, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2025 MRQ Cash & cash equivalent	Mar 31 2025 MRQ Current Liabilities
Altimmune inc	139.11	$ 149.826 Millions	$ 1.077 Millions
Bridgebio Oncology Therapeutics Inc	112.67	$ 200.963 Millions	$ 1.784 Millions
Psyence Biomedical ltd	74.95	$ 6.135 Millions	$ 0.082 Millions
Tao Synergies Inc	70.40	$ 14.833 Millions	$ 0.211 Millions
Disc Medicine Inc	64.08	$ 694.662 Millions	$ 10.841 Millions
Janux Therapeutics Inc	57.94	$ 1,014.146 Millions	$ 17.502 Millions
Third Harmonic Bio Inc	53.24	$ 271.611 Millions	$ 5.102 Millions
Gh Research Plc	51.31	$ 244.954 Millions	$ 4.774 Millions
Context Therapeutics Inc	47.02	$ 89.352 Millions	$ 1.900 Millions
Essa Pharma inc	46.53	$ 86.324 Millions	$ 1.855 Millions
Inhibitor Therapeutics Inc	45.63	$ 4.322 Millions	$ 0.095 Millions
Upstream Bio Inc	45.09	$ 431.380 Millions	$ 9.567 Millions
Viking Therapeutics Inc	44.66	$ 851.858 Millions	$ 19.075 Millions
Belite Bio Inc	36.61	$ 352.932 Millions	$ 9.641 Millions
Bright Minds Biosciences Inc	35.59	$ 63.669 Millions	$ 1.789 Millions
Roivant Sciences Ltd	32.71	$ 4,886.891 Millions	$ 149.411 Millions
Septerna Inc	31.59	$ 336.005 Millions	$ 10.638 Millions
Jade Biosciences Inc	31.53	$ 76.210 Millions	$ 2.417 Millions
Terns Pharmaceuticals Inc	30.57	$ 334.264 Millions	$ 10.935 Millions
Rapport Therapeutics Inc	30.41	$ 285.382 Millions	$ 9.383 Millions
Arca Biopharma Inc	29.78	$ 349.094 Millions	$ 11.723 Millions
Xbiotech Inc	28.82	$ 155.897 Millions	$ 5.410 Millions
Tvardi Therapeutics Inc	28.54	$ 34.217 Millions	$ 1.199 Millions
Vera Therapeutics Inc	28.49	$ 589.834 Millions	$ 20.703 Millions
Fulcrum Therapeutics Inc	27.98	$ 226.603 Millions	$ 8.100 Millions
Design Therapeutics Inc	27.89	$ 229.674 Millions	$ 8.236 Millions
Monopar Therapeutics Inc	26.62	$ 39.711 Millions	$ 1.492 Millions
Immunome Inc	26.18	$ 317.323 Millions	$ 12.119 Millions
Agios Pharmaceuticals Inc	25.40	$ 893.375 Millions	$ 35.170 Millions
Aardvark Therapeutics Inc	25.31	$ 151.260 Millions	$ 5.976 Millions

Date modified: 2026-09-08T15:11:30+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.